Filing search / Inhibrx Biosciences, Inc. / "Innovation"

8-K

EX-99.2

INBX Inhibrx Biosciences, Inc.

7 Aug 23

Inhibrx Reports Second Quarter 2023 Financial Results

4:05pm

INBX Investor Presentation Outcomes Focused August 2023 Innovation Driven 2 Presentation disclaimer This presentation contains forward-looking

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

16 Nov 22

Regulation FD Disclosure

9:01am

Outcomes Focused Innovation Driven November 2022 2 This presentation contains forward-looking statements. In some cases, you can identify forward … Anchored by innovation and protein-engineering expertise Inhibrx’s modular sdAb platform + Ability to precision engineer to specific target biology

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

4 Oct 22

Entry into a Material Definitive Agreement

8:02am

Outcomes Focused Innovation Driven October 2022 2 This presentation contains forward-looking statements. In some cases, you can identify forward … innovation and execution PARTNERSHIPS WITH INDUSTRY LEADERS All platforms and programs developed in-house with strong patent protection Inhibrx’s

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

10 Aug 22

Regulation FD Disclosure

4:06pm

Outcomes Focused Innovation Driven August 2022 2 This presentation contains forward-looking statements. In some cases, you can identify forward … + Proven innovation and execution PARTNERSHIPS WITH INDUSTRY LEADERS All platforms and programs developed in-house with strong patent protection

8-K

EX-99.1

e816tt9eyvux es1z

30 Jun 22

Regulation FD Disclosure

9:01am

8-K

EX-99.1

egcgxg

16 May 22

Regulation FD Disclosure

9:03am

8-K

EX-99.1

lpukqz

4 Apr 22

Regulation FD Disclosure

4:06pm

8-K

EX-99.2

4vn313a qh6

4 Jan 22

Regulation FD Disclosure

4:41pm

8-K

EX-99.2

mr7uk1 iszzd99ivr3

12 Oct 21

Regulation FD Disclosure

7:50am

8-K

EX-99.2

kjz5ppz dyhn

21 Jun 21

Entry into a Material Definitive Agreement

4:05pm

8-K

EX-99.2

pqwl1ttbyp2b8

12 Mar 21

Results of Operations and Financial Condition

8:55am

10-K

u0zbk5u4mnjw

12 Mar 21

Annual report

8:46am

8-K

EX-99.2

ljn9dv kf5nlwo

5 Jan 21

Inhibrx Announces Phase 1 Dose Escalation Results of

12:00am

10-Q

x1oilrxe wqkj4yxb4

13 Nov 20

Quarterly report

4:09pm

8-K

EX-99.2

hjtt2evj ean

12 Nov 20

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

6:07am

8-K

EX-99.1

3ehjmvay77m

11 Sep 20

Regulation FD Disclosure

4:24pm

424B4

9ipytma0j

19 Aug 20

Prospectus supplement with pricing info

5:21pm